ArticleThe oncologist2022

An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer.

Cara Mathews et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.